JP2011509244A - 脳の原発性神経腫瘍および神経膠腫における脳腫瘍幹細胞マーカーならびに診断および治療標的としてのｃｄ２４ - Google Patents

脳の原発性神経腫瘍および神経膠腫における脳腫瘍幹細胞マーカーならびに診断および治療標的としてのｃｄ２４ Download PDF

Info

Publication number
JP2011509244A
JP2011509244A JP2010539934A JP2010539934A JP2011509244A JP 2011509244 A JP2011509244 A JP 2011509244A JP 2010539934 A JP2010539934 A JP 2010539934A JP 2010539934 A JP2010539934 A JP 2010539934A JP 2011509244 A JP2011509244 A JP 2011509244A
Authority
JP
Japan
Prior art keywords
subject
tumor
specific targeting
brain tumor
brain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2010539934A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011509244A5 (https=
Inventor
スティーブン エイ． ゴールドマン
フレーザー シム
ロマーヌ メラニー オーヴェルニュ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Rochester
Original Assignee
University of Rochester
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Rochester filed Critical University of Rochester
Publication of JP2011509244A publication Critical patent/JP2011509244A/ja
Publication of JP2011509244A5 publication Critical patent/JP2011509244A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/14—Heterocyclic carbon compound [i.e., O, S, N, Se, Te, as only ring hetero atom]
    • Y10T436/142222—Hetero-O [e.g., ascorbic acid, etc.]
    • Y10T436/143333—Saccharide [e.g., DNA, etc.]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
JP2010539934A 2007-12-21 2008-12-22 脳の原発性神経腫瘍および神経膠腫における脳腫瘍幹細胞マーカーならびに診断および治療標的としてのｃｄ２４ Pending JP2011509244A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US1638107P 2007-12-21 2007-12-21
PCT/US2008/087977 WO2009086284A1 (en) 2007-12-21 2008-12-22 Cd24 as a brain tumor stem cell marker and a diagnostic and therapeutic target in primary neaural and glial tumors of the brain

Publications (2)

Publication Number Publication Date
JP2011509244A true JP2011509244A (ja) 2011-03-24
JP2011509244A5 JP2011509244A5 (https=) 2012-05-17

Family

ID=40824698

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010539934A Pending JP2011509244A (ja) 2007-12-21 2008-12-22 脳の原発性神経腫瘍および神経膠腫における脳腫瘍幹細胞マーカーならびに診断および治療標的としてのｃｄ２４

Country Status (5)

Country Link
US (1) US20110002846A1 (https=)
EP (1) EP2231184A4 (https=)
JP (1) JP2011509244A (https=)
CA (1) CA2709380A1 (https=)
WO (1) WO2009086284A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20201651T1 (hr) * 2015-05-07 2020-12-25 Oncoimmune, Inc. Uporaba cd24 za snižavanje razina lipoproteina niske gustoće kolesterola
CN114381491A (zh) * 2020-10-22 2022-04-22 复旦大学附属儿科医院 一种神经母细胞瘤相关的肿瘤细胞标志物及其应用
CN116478999B (zh) * 2023-01-16 2024-04-05 广西师范大学 免疫抑制分子cd24核酸适体的筛选及应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005084390A2 (en) * 2004-03-02 2005-09-15 Seattle Genetics, Inc. Partially loaded antibodies and methods of their conjugation
WO2006065533A2 (en) * 2004-11-29 2006-06-22 Seattle Genetics, Inc. Engineered antibodies and immunoconjugates
JP2007527421A (ja) * 2004-02-23 2007-09-27 ジェネンテック・インコーポレーテッド 複素環式自壊的リンカーおよび結合体

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1766017B1 (en) * 2004-06-10 2015-01-21 Viventia Bio Inc. Tumor specific antibody
CA2632675A1 (en) * 2005-12-08 2007-07-05 Lionel J. Coignet Diagnostic and therapeutic strategies for conditions associated with the flj13639 gene
KR20080002341A (ko) * 2006-06-30 2008-01-04 재단법인서울대학교산학협력재단 Ｃｄ２４를 표적으로 하는 암 억제방법
WO2009063461A1 (en) * 2007-11-14 2009-05-22 The Medical Research, Infrastructure, And Health Services Fund Of The Tel Aviv Medical Center Methods of treating cancer using anti cd24 antibodies

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007527421A (ja) * 2004-02-23 2007-09-27 ジェネンテック・インコーポレーテッド 複素環式自壊的リンカーおよび結合体
WO2005084390A2 (en) * 2004-03-02 2005-09-15 Seattle Genetics, Inc. Partially loaded antibodies and methods of their conjugation
WO2006065533A2 (en) * 2004-11-29 2006-06-22 Seattle Genetics, Inc. Engineered antibodies and immunoconjugates

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
JPN6013023191; Ｃ．Ｐｏｎｃｅｔ，　ｅｔ　ａｌ．，　Ａｃｔａ　Ｎｅｕｒｏｐａｔｈｏｌ．，　１９９６，　９１，　ｐｐ４００-４０８ *
JPN6013023192; Ｋ．Ｂｏｏｎ，　ｅｔ　ａｌ．，　Ｏｎｃｏｇｅｎｅ，　２００３，　２２，　ｐｐ７６８７-７６９４ *
JPN6013023194; Ｖ．Ｓｅｎｎｅｒ，　ｅｔ　ａｌ．，　Ｊｏｕｒｎａｌ　ｏｆ　Ｎｅｕｒｏｐａｔｈｏｌｏｇｙ　ａｎｄ　Ｅｘｐｅｒｉｍｅｎｔａｌ　Ｎｅｕｒｏｌｏｇｙ，　１９９９，　５８（８），　ｐｐ７９５-８０２ *
JPN6013023196; Ｔ．Ｆｕｋｕｓｈｉｍａ，　ｅｔ　ａｌ．，　Ｔｈｅ　Ｊｏｕｒｎａｌ　ｏｆ　Ｂｉｏｌｏｇｉｃａｌ　Ｃｈｅｍｉｓｔｒｙ，　Ｊｕｎｅ．２００７，　２８２（２５），　ｐｐ１８６３４-１８６４４ *

Also Published As

Publication number Publication date
WO2009086284A1 (en) 2009-07-09
CA2709380A1 (en) 2009-07-09
US20110002846A1 (en) 2011-01-06
EP2231184A1 (en) 2010-09-29
EP2231184A4 (en) 2012-02-15

Similar Documents

Publication Publication Date Title
US7531171B2 (en) Antibodies to non-functional P2X7 receptor
JP7308191B2 (ja) 抗ｃｄ４７剤ベースの卵巣癌療法
US6767541B2 (en) HER-2/neu overexpression abrogates growth inhibitory pathways
US20030082188A1 (en) Treatment of prostate cancer by inhibitors of NCAM2
JP2021073237A (ja) 中枢神経系における悪性腫瘍の検出及び治療
US8093010B2 (en) Angiogenesis inhibiting molecules, their selection, production and their use in the treatment of cancer
JP6941565B2 (ja) がん転移を処置または防止するのに有用な化合物および組成物、ならびにこれらの使用法
CN114929263A (zh) 胞间黏附分子1（icam1）抗体药物缀合物及其用途
KR101741898B1 (ko) Claudin 7을 포함하는 방사선 반응성 위암 진단용 바이오마커 조성물
CA2420226C (en) Methods for treating demyelinating diseases
JP2011509244A (ja) 脳の原発性神経腫瘍および神経膠腫における脳腫瘍幹細胞マーカーならびに診断および治療標的としてのｃｄ２４
US7892767B2 (en) Phosphospecific chemokine receptor antibodies
JP4365583B2 (ja) ノッチレセプターアゴニスト及び用途
AU2001288286A1 (en) Methods for treating demyelinating diseases
JP6854765B2 (ja) 標的への抗癌剤の送達を増加させる方法
US20050260132A1 (en) Monoclonal antibodies directed to receptor protein tyrosine phosphatase zeta
US7906104B2 (en) Methods for detecting pancreatic beta-islet cells and diseases thereof
US20040096446A1 (en) Methods for treating demyelinating diseases
CN121108340A (zh) RORl的抗体及其制备方法和用途
WO2025199292A1 (en) A humanized monoclonal antibody to sfrp2 for tumor associated macrophage reduction and polarization in cancer
AU2007201935A1 (en) Methods for treating demyelinating disease
JP2020176905A (ja) 卵巣癌の検出方法及び卵巣癌治療剤
JP2004513081A (ja) ＮＮＴ−１インヒビターを使用してＩｇＥ関連疾患を治療するための方法および組成物

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20111219

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120319

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130515

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20130812

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20130819

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20140430

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20141119